Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a ...
TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results